Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy.
Nguyen T, Carrieri FA, Connis N, Lafargue A, Chang J, Chan A, Shetty AC, Song Y, Hoang T, Jagtap S, Chowdhury DD, Khan MA, Gabrielson KL, Rezaee M, Torres-Ayuso P, Brognard J, Hann CL, Tran PT. Nguyen T, et al. Among authors: chang j. Mol Cancer Ther. 2024 Jun 10:OF1-OF11. doi: 10.1158/1535-7163.MCT-23-0412. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38853421
Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.
Wang X, Raman N, Lemtiri-Chlieh G, Chang J, Jagtap S, Chowdhury DD, Ballew M, Carrieri FA, Nguyen T, Nugent K, Peck T, Levine MS, Chan A, Lam C, Malek R, Hoang T, Phillips R, Cheng Z, Taparra K, Connis N, Hann CL, Holland A, Tran PT, Lafargue A, Wang H. Wang X, et al. Among authors: chang j. Mol Cancer Ther. 2023 Apr 3;22(4):519-528. doi: 10.1158/1535-7163.MCT-22-0191. Mol Cancer Ther. 2023. PMID: 36752776 Free PMC article.
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy.
Nguyen T, Carrieri FA, Connis N, Lafargue A, Chang J, Chan A, Shetty AC, Song Y, Hoang T, Jagtap S, Chowdhury DD, Khan MA, Gabrielson KL, Rezaee M, Torres-Ayuso P, Brognard J, Hann CL, Tran PT. Nguyen T, et al. Among authors: chang j. Mol Cancer Ther. 2024 Apr 27. doi: 10.1158/1535-7163.MCT-23-0412. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38670554
TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
Hoang T, Sutera P, Nguyen T, Chang J, Jagtap S, Song Y, Shetty AC, Chowdhury DD, Chan A, Carrieri FA, Hathout L, Ennis R, Jabbour SK, Parikh R, Molitoris J, Song DY, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Lafargue A, Van Der Eecken K, Bunz F, Ost P, Tran PT, Deek MP. Hoang T, et al. Among authors: chang j. Prostate. 2024 Jan;84(1):87-99. doi: 10.1002/pros.24629. Epub 2023 Oct 9. Prostate. 2024. PMID: 37812042
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
Sutera P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, Song Y, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, Tran PT. Sutera P, et al. Among authors: chang jh. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1095-1101. doi: 10.1016/j.ijrobp.2022.12.006. Epub 2023 Jan 26. Int J Radiat Oncol Biol Phys. 2023. PMID: 36708787 Free PMC article.
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, Rana Z, Ren L, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Song DY, Pienta K, Feng FY, Joniau S, Lotan T, Lane B, Kiess A, Rowe S, Pomper M, DeWeese T, Deek M, Sweeney C, Ost P, Tran PT. Sutera P, et al. Among authors: chang j. Eur Urol. 2023 Dec;84(6):531-535. doi: 10.1016/j.eururo.2023.04.025. Epub 2023 May 10. Eur Urol. 2023. PMID: 37173210 Free PMC article.
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHERINE Study Group. Geyer CE Jr, et al. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070. N Engl J Med. 2025. PMID: 39813643 Clinical Trial.
21,730 results
You have reached the last available page of results. Please see the User Guide for more information.